Author

B. Hanratty

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Assay:whole-genome sequencing· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

c. Morrissey· 2 shared E. Corey· 2 shared G. Ha· 2 shared I. Coleman· 2 shared M. Haffner· 2 shared P. S. Nelson· 2 shared A. Bankhead· 1 shared A. Bose· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

c. Morrissey

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

S. Frank, T. Persse, I. M. Coleman, A. Bankhead, D. Li, N. DeSarkar, D. Wilson, D. Rudoy, M. Vashisth, P. Galipeau, M. Yang, B. Hanratty, R. Dumpit, c. Morrissey, E. Corey, , P. S. Nelson

This study shows that acute CDK12 loss in prostate cancer causes HR deficiency via polyadenylation, but chronic loss leads to adaptation, making PARP inhibitors ineffective and suggesting CDK13 targeting as a new therapeutic approach.

bioRxiv · Jul 16, 2024 · PreprintCancer Biology

Differential response to LSD1 inhibition in prostate cancer reveals a YAP1 vulnerability in the neuroendocrine subtype

S. Jasim, R. Kumar, S. Kim, T. Krueger, I. Coleman, S. Dalrymple, L. Antony, D. Rosen, B. Hanratty, R. Patel, P. Nelson, Z. Aghaei, J. Beumer, M. Haffner, T. Lotan, , W. Brennen

This paper shows that LSD1 inhibition is effective against neuroendocrine prostate cancer (NEPC) and that combining it with YAP/TEAD inhibition enhances treatment efficacy.

bioRxiv · Jan 17, 2024 · PreprintCancer Biology

Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes

N. De Sarkar, R. D. Patton, A.-L. Doebley, B. Hanratty, A. J. Kreitzman, J. F. Sarthy, M. Ko, M. Adil, S. Brahma, M. P. Meers, D. H. Janssens, L. S. Ang, I. Coleman, A. Bose, R. F. Dumpit, , G. Ha

This paper identifies nucleosome patterns in ctDNA that distinguish advanced prostate cancer phenotypes, achieving high accuracy in classification using a prediction model.

bioRxiv · Jun 21, 2022Cancer Biology